



Madrid, November 3, 2025

Making Science Group, S.A. (hereinafter "Making Science", "Making Science Group", the "Company", or the "Group"), pursuant to the provisions of Article 17 of Regulation (EU) No. 596/2014 on market abuse, Article 227 of Law 6/2023 of 17 March on Securities Markets and Investment Services, and concordant provisions, as well as Circular 3/2020 of the BME Growth segment of BME MTF Equity (hereinafter "BME Growth"), hereby brings to your attention the following:

OTHER RELEVANT INFORMATION

Making Science informed the market, through the Privileged Information published on October 4, 2025, of the sale of its Cloud and Cybersecurity business unit in Spain to Lutech S.p.A. As a result of this transaction, valued at approximately €26 million and expected to close in the fourth quarter of 2025, the consolidated results presented on October 30 for the first half of 2025 do not include the recurring EBITDA of the aforementioned business unit (as IFRS 5 is applied, which involves recording the net result of that business unit in the consolidated income statement under the heading "Profit for the year from discontinued operations").

As a result of the above, the Company's Board of Directors, on October 29, 2025, agreed to suspend the guidance for 2025 as published in the interim financial statements.

Making Science will update its market information, including the revision of its 2027 strategic plan, with the aim of fully incorporating the opportunities arising from this transaction and its impact on the Ad Machina and Making Science Marketing & AdTech units.

Sincerely yours,

José Antonio Martínez Aguilar
Chief Executive Officer of Making Science Group, S.A.